Compare HDSN & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HDSN | CERS |
|---|---|---|
| Founded | 1991 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.9M | 276.0M |
| IPO Year | 1996 | 1996 |
| Metric | HDSN | CERS |
|---|---|---|
| Price | $5.50 | $2.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 594.2K | ★ 2.3M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $237,118,000.00 | $51,326,000.00 |
| Revenue This Year | $2.51 | $19.95 |
| Revenue Next Year | $2.38 | $8.84 |
| P/E Ratio | $527.00 | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $4.64 | $1.15 |
| 52 Week High | $10.52 | $3.15 |
| Indicator | HDSN | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 51.94 | 58.58 |
| Support Level | $4.64 | $1.84 |
| Resistance Level | $6.49 | $2.91 |
| Average True Range (ATR) | 0.21 | 0.18 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 96.07 | 58.13 |
Hudson Technologies Inc is an American industrial products manufacturer. It develops products which are mainly used in commercial air conditioning, industrial processing, and refrigeration systems. The company products include refrigerant and industrial gases, refrigerant management services and RefrigerantSide services, which consist of system decontamination. These are performed at customer's site using its Zugibeast system, which is a fast and portable system and allows the R-Side services team to accelerate critical services while saving customers time, money and aggravation. The company also owns a web-based real-time monitoring service which is used in the facility's refrigeration systems and other energy systems.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.